Metabolic Reprogramming in Renal Tubular Cells in Acute Kidney Injury Following Severe Trauma
NCT ID: NCT06167512
Last Updated: 2024-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
80 participants
OBSERVATIONAL
2024-06-27
2025-10-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Because of the variability of lesions in these patients, and the multiplicity of pathways activated, the mechanisms involved and their causality with organ failure following severe trauma, are still poorly understood. Given their frequency and importance in terms of morbidity and mortality, the investigators decided to take a particular interest in the mechanisms leading to renal and pulmonary injury. The investigators' hypothesis is that the study of urinary and blood markers not performed as part of clinical routine would provide a better understanding of the pathophysiological mechanisms leading to organ failure secondary to severe trauma, and more specifically to renal and pulmonary injuries. With TRAUMATEC study, the investigators will explore mechanisms leading to AKI and ARDS through blood and urine samples of 60 severe trauma patients sampled over the first 48 hours after ICU admission and a reference of 20 healthy volunteers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Kidney Injury in Severe Trauma
NCT03433079
Outcomes of Critically Ill Patients With Severe Acute Kidney Injury Requiring Renal Replacement Therapy
NCT02897310
Acute Kidney Attack in Severe Traumatized Patients
NCT03877978
Renal Perfusion and the Development of AKI Following Traumatic Injury
NCT06917053
Continuous Renal Replacement Therapy Doses in Critically Ill Patients With Acute Kidney Injury
NCT06901011
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Blood and urine samples will be collected at ICU arrival, 12-, 24- and 48- hours after ICU admission. Specific dosages will then be realized on blood and urines to study metabolic and hormonal pathway leading to AKI and ARDS.
The primary objective of the study is to explore the association between renal metabolic changes and renal function impairment following severe trauma.
Secondary objectives are (1) to explore mitochondrial changes observed at the renal cellular level, on in vitro renal culture cells after exposure to trauma patient serum (2) to explore the association between plasma metabolic changes and renal and pulmonary function impairment following severe trauma (3) to explore the association between hormonal metabolic changes and renal and pulmonary function impairment following severe trauma (4) to explore the association between red blood cell-induced oxidative stress and renal function impairment following severe trauma (5) to explore the association between changes in the hemoglobin recycling (chelation) system and impaired renal function following severe trauma (6) to explore renal tubular damage secondary to severe trauma (7) to explore the pathophysiological mechanisms associated with pulmonary damage following severe trauma (8) to describe mortality at day 30.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
polytrauma patients
polytrauma patients
No interventions assigned to this group
healthy volunteers
healthy volunteers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients (age ≥ 18 years)
* Patient admitted for suspected severe trauma (1 Vittel criteria)
* Injury Severity Score ≥ 9
* Health insurance
* Written consent obtained from the patient or trusted support person / family member / close friend, or inclusion in an emergency situation and written consent obtained from the patient (trusted support person / family member / close friend if necessary) as soon as possible (article L1122-1-2 of the CSP).
Healthy volunteers :
* Adult patients (≥ 18 years)
* Affiliated with health insurance
* Written informed consent́
* Patient respecting matching
Exclusion Criteria
* Pregnant patient
* Minor patient
* Adult under guardianship, curatorship or safeguard of justice
* Patient under Aide Médicale d'État
* Chronic renal failure on dialysis
* Chronic respiratory disease
* Patient with chronic cardiac insufficiency
* Systemic inflammatory disease
Healthy volunteers :
* Pregnant patient
* Minor patient
* Adult under guardianship, curatorship or safeguard of justice
* Patient under Aide Médicale d'État
* Patient with chronic renal failure on dialysis
* Chronic respiratory disease
* Patient with chronic cardiac insufficiency
* Systemic inflammatory disease
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bicetre hospital
Le Kremlin-Bicêtre, , France
Bicetre hospital
Le Kremlin-Bicêtre, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01597-38
Identifier Type: OTHER
Identifier Source: secondary_id
APHP231084
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.